Clinical advancements include setmelanotide (IMCIVREETM, Rhythm Pharmaceuticals), an MC4R agonist approved for monogenic obesity disorders (POMC, LepR deficiencies). This evidence concerns the gene POMC and obesity due to melanocortin 4 receptor deficiency.